Giuseppe Saglio

Giuseppe Saglio

UNVERIFIED PROFILE

Are you Giuseppe Saglio?   Register this Author

Register author
Giuseppe Saglio

Giuseppe Saglio

Publications by authors named "Giuseppe Saglio"

Are you Giuseppe Saglio?   Register this Author

100Publications

3131Reads

32Profile Views

Synergistic effect of eltrombopag and deferasirox in aplastic anemia: a clinical case and review of the literature.

Leuk Lymphoma 2020 Jan 10;61(1):234-236. Epub 2019 Sep 10.

Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1660969DOI Listing
January 2020

Highly Sensitive Detection of Mutations in Acute Myeloid Leukemia.

J Clin Med 2020 Jan 19;9(1). Epub 2020 Jan 19.

Department of Clinical and Biological Sciences of the University of Turin, San Luigi Gonzaga Hospital, Regione Gonzole 10, 10043 Orbassano (Turin), Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm9010271DOI Listing
January 2020

Bone marrow microenvironment: The guardian of leukemia stem cells.

World J Stem Cells 2019 Aug;11(8):476-490

Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran 146651157, Iran.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4252/wjsc.v11.i8.476DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6716085PMC
August 2019

Precision tyrosine kinase inhibitor dosing in chronic myeloid leukemia?

Haematologica 2019 05;104(5):862-864

Haematology Research Center, Division of Experimental Medicine, Department of Medicine, Imperial College London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.214445DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518890PMC
May 2019

Digital PCR in Myeloid Malignancies: Ready to Replace Quantitative PCR?

Int J Mol Sci 2019 May 7;20(9). Epub 2019 May 7.

Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20092249DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540058PMC
May 2019

Nilotinib in the treatment of chronic myeloid leukemia.

Future Oncol 2019 Mar 14;15(9):953-965. Epub 2018 Dec 14.

Division of Hematology & Internal Medicine, Department of Clinical & Biological Sciences of the University of Turin, 'San Luigi Gonzaga' University Hospital, 10043 Orbassano-Turin, Italy.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon-2018-0468
Publisher Site
http://dx.doi.org/10.2217/fon-2018-0468DOI Listing
March 2019

Chronic Myeloproliferative Neoplasms: Some Remaining Challenges.

Hemasphere 2018 Oct 2;2(5):e147. Epub 2018 Oct 2.

University of California Irvine, Irvine, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/HS9.0000000000000147DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407801PMC
October 2018

Expressional changes in stemness markers post electrochemotherapy in pancreatic cancer cells.

Bioelectrochemistry 2018 Aug 15;122:84-92. Epub 2018 Mar 15.

Cork Cancer Research Centre, Western Gateway Building, University College Cork, Ireland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bioelechem.2018.03.009DOI Listing
August 2018

First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.

Leuk Lymphoma 2018 07 3;59(7):1523-1538. Epub 2017 Oct 3.

b Department of Leukemia, Division of Cancer Medicine , The University of Texas MD Anderson Cancer Center , Houston , Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1379074DOI Listing
July 2018

Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient-Physician Perspective.

Clin Lymphoma Myeloma Leuk 2018 06 25;18(6):375-379. Epub 2018 Apr 25.

Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.04.005DOI Listing
June 2018

Present results and future perspectives in optimizing chronic myeloid leukemia therapy.

Haematologica 2018 06;103(6):928-930

Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2017.182022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058801PMC
June 2018

Dasatinib dose management for the treatment of chronic myeloid leukemia.

Cancer 2018 04 25;124(8):1660-1672. Epub 2018 Jan 25.

Department of Hematology and Oncology, Versailles Medical Center, INSERM UMR 1173, University of Versailles Saint-Quenti-en-Yvelines, Paris Saclay, Le Chesnay, France.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31232
Publisher Site
http://dx.doi.org/10.1002/cncr.31232DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901015PMC
April 2018

Prognostic significance of The Wilms' Tumor-1 (WT1) rs16754 polymorphism in acute myeloid leukemia.

Leuk Res 2018 04 5;67:6-11. Epub 2018 Feb 5.

Department of Clinical and Biological Sciences, University of Turin, Turin, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.01.016DOI Listing
April 2018

Unleashing the Guardian: The Targetable BCR-ABL/HAUSP/PML/PTEN Network in Chronic Myeloid Leukemia.

Curr Drug Targets 2017 ;18(4):389-395

Department of Clinical and Biological Sciences, University of Turin, regione Gonzole 10, 10043, Orbassano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1389450117666160608120527DOI Listing
September 2017

Specific Monoclonal Antibody Against Bcr/Abl Out-of-Frame Alternative Proteins as Diagnostic Tool in Chronic Myelogenous Leukemia Patients.

Monoclon Antib Immunodiagn Immunother 2017 Aug 13;36(4):149-156. Epub 2017 Jul 13.

2 Department of Medical Biotechnologies and Translational Medicine, School of Medicine, University of Milan , Milan, Italy .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/mab.2016.0054DOI Listing
August 2017

Modeling myeloproliferative neoplasms: From mutations to mouse models and back again.

Blood Rev 2017 05 24;31(3):139-150. Epub 2016 Nov 24.

Department of Molecular Biotechnology and Health Sciences, University of Torino, via Nizza, 52, 10126 Torino, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2016.11.004DOI Listing
May 2017

The biology of CML supports second-generation TKIs as frontline treatment.

Clin Adv Hematol Oncol 2017 Apr;15(4):302-307

University of Turin, Mauriziano Hospital, Turin, Italy.

View Article

Download full-text PDF

Source
April 2017

Clinical significance of TFR2 and EPOR expression in bone marrow cells in myelodysplastic syndromes.

Br J Haematol 2017 02 23;176(3):491-495. Epub 2016 Feb 23.

Dipartimento di Scienze Cliniche e Biologiche, AOU San Luigi Gonzaga, Università di Torino, Orbassano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13968DOI Listing
February 2017

Mimicking the Acute Myeloid Leukemia Niche for Molecular Study and Drug Screening.

Tissue Eng Part C Methods 2017 02 13;23(2):72-85. Epub 2017 Jan 13.

1 Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine , Tehran, Iran .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/ten.TEC.2016.0404DOI Listing
February 2017

IκB-α: At the crossroad between oncogenic and tumor-suppressive signals.

Oncol Lett 2017 Feb 6;13(2):531-534. Epub 2016 Dec 6.

Department of Clinical and Biological Sciences, University of Turin, I-10043 Orbassano, Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ol.2016.5465DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351326PMC
February 2017

The targetable role of herpes virus-associated ubiquitin-specific protease (HAUSP) in p190 BCR-ABL leukemia.

Oncol Lett 2016 Nov 1;12(5):3123-3126. Epub 2016 Sep 1.

Department of Clinical and Biological Sciences, 'San Luigi Gonzaga' University Hospital, School of Medicine, University of Turin, 10043 Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ol.2016.5073DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5103907PMC
November 2016

Mechanisms of p53 Functional De-Regulation: Role of the IκB-α/p53 Complex.

Int J Mol Sci 2016 Nov 29;17(12). Epub 2016 Nov 29.

Department of Clinical and Biological Sciences, University of Turin, Regione Gonzole 10, 10043 Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms17121997DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5187797PMC
November 2016

A comparative study of myocardial molecular phenotypes of two tfr2β null mice: role in ischemia/reperfusion.

Biofactors 2015 Sep-Oct;41(5):360-71. Epub 2015 Oct 13.

Department of Clinical and Biological Sciences, University of Torino, AOU San Luigi Gonzaga, Orbassano, Torino, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/biof.1237DOI Listing
September 2016

Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.

Clin Lymphoma Myeloma Leuk 2016 08 1;16 Suppl:S96-S100. Epub 2016 Apr 1.

Department of Clinical and Biological Sciences, University of Turin, Azienda Ospedaliero-Universitaria San Luigi Gonzaga, Orbassano (TO), Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2016.03.008DOI Listing
August 2016

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.

J Clin Oncol 2016 07 23;34(20):2333-40. Epub 2016 May 23.

Jorge E. Cortes and Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center, Houston, TX; Neil P. Shah, University of California San Francisco School of Medicine, San Francisco, CA; Brigid Bradley-Garelik and George Manos, Bristol-Myers Squibb, Princeton, NJ; Giuseppe Saglio, University of Turin, Turin; Michele Baccarani, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy; Jiří Mayer, University Hospital Brno and Central European Institute of Technology, Masaryk University, Brno, Czech Republic; Concepción Boqué, Institut Català d'Oncologia, Hospital Duran i Reynals, L'Hospitalet, Barcelona, Spain; Charles Chuah, Singapore General Hospital, Duke-National University of Singapore Medical School, Singapore; Luis Casanova, Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú;and Andreas Hochhaus, Universitätsklinikum Jena, Jena, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.8899DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118045PMC
July 2016

Ponatinib for chronic myeloid leukaemia: future perspectives.

Lancet Oncol 2016 05 12;17(5):546-7. Epub 2016 Apr 12.

Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, 10043 Orbassano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)30064-XDOI Listing
May 2016

The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phase.

BMC Cancer 2016 05 16;16:314. Epub 2016 May 16.

Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Regione Gonzole 10, 10043, Orbassano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-016-2346-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869339PMC
May 2016

Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias.

Adv Hematol 2015 30;2015:612567. Epub 2015 Dec 30.

Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2015/612567DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710905PMC
February 2016

BCR-ABL1 mutation ≠ ponatinib resistance.

Blood 2016 Feb;127(6):666-7

UNIVERSITY OF TURIN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-12-685149DOI Listing
February 2016

BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation.

Cell Cycle 2015 ;14(7):973-9

a Department of Clinical and Biological Sciences; San Luigi Hospital ; Orbassano - Turin University ; Turin , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384101.2015.1006970DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4615112PMC
December 2015

The Role of PTEN in Myeloid Malignancies.

Hematol Rep 2015 Nov 9;7(4):5844. Epub 2015 Dec 9.

Department of Clinical and Biological Sciences, University of Turin , Orbassano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4081/hr.2015.6027DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691678PMC
November 2015

Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL Shows Deep Molecular Responses in Long-Term Post-Allogeneic Stem Cell Transplantation Chronic Myeloid Leukemia Patients.

Biol Blood Marrow Transplant 2015 Oct 4;21(10):1852-5. Epub 2015 Jul 4.

Division of Hematology, Chaim Sheba Medical Center Tel Hashomer, Ramat-Gan, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2015.06.018DOI Listing
October 2015

BCR-ABL promotes PTEN downregulation in chronic myeloid leukemia.

PLoS One 2014 24;9(10):e110682. Epub 2014 Oct 24.

Department of Clinical and Biological Sciences, San Luigi Hospital, University of Turin, Orbassano, Turin, Italy.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0110682PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4208795PMC
June 2015

Update on emerging treatments for chronic myeloid leukemia.

Expert Opin Emerg Drugs 2015 Jun 31;20(2):183-96. Epub 2015 Mar 31.

University of Turin, San Luigi Hospital, Department of Clinical and Biological Sciences , Orbassano 10043 , Italy

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728214.2015.1031217DOI Listing
June 2015

Milestones and monitoring.

Curr Hematol Malig Rep 2015 Jun;10(2):167-72

Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences of the University of Turin, "San Luigi Gonzaga" University Hospital, 10043, Orbassano, Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-015-0258-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445481PMC
June 2015

Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.

Am J Hematol 2015 Apr 30;90(4):E66-72. Epub 2015 Jan 30.

Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23938DOI Listing
April 2015

The choice of first-line chronic myelogenous leukemia treatment.

Ann Hematol 2015 Apr 27;94 Suppl 2:S123-31. Epub 2015 Mar 27.

Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences, University of Turin, "San Luigi Gonzaga" University Hospital, 10043, Orbassano, Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-015-2321-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4375302PMC
April 2015